Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-06
2007-02-06
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S341000, C514S397000, C546S210000, C546S274100, C548S315700
Reexamination Certificate
active
11058168
ABSTRACT:
The present invention relates to 1,2,4-tri-substituted imidazoline derivatives, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said imidazoline derivatives, to methods for the preparation of these intermediates, to pharmaceutical compositions containing one or more of these imidazoline derivatives as active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders. The compounds have the general formula (I)wherein the symbols have the meanings given in the specification.
REFERENCES:
patent: 5952535 (1999-09-01), King et al.
patent: 6960601 (2005-11-01), Smith et al.
patent: 2004/0122074 (2004-06-01), Dow et al.
patent: 2004/0235854 (2004-11-01), Kruse et al.
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/078413 (2003-09-01), None
Dyck et al., “Potent Imidazole and Triazole CB1 receptor Antagonists Related to SR141716,”Bioorganic & Medicinal Chemistry Letters, vol. 14, Iss. 5, pp. 1151-1154 (2004).
Co-Pending U.S. National Stage Application to Josephus H.M. Lange et al., based on International Patent Application No. PCT/EP2005/050680, filed Aug. 15, 2006.
International Preliminary Report on Patentability for International Application No. PCT/EP/2005/050680 (International Publication No. WO 2005/080345), Examiner I. Scruton-Evans, Nov. 16, 2005.
Khanna et al, “Selective Cyclooxygenase-2 Inhibitors: Heteroaryl Modified 1,2-Diarylimidazoles Are Potent, Orally Active Antiinflammatory Agents,”J. Med. Chem, 2000, 43, 3168-3185.
Lange et al., “Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Elective CB1Cannabinoid Receptor Antagonists,”J. Med. Chem., 204, 47, 627-643 (2003).
International Search Report for corresponding PCT application No. PCT/EP2005/050680.
Kruse Cornelis G.
Lange Josephus H. M.
Van Stuivenberg Herman H.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Freistein Andrew B.
McKane Joseph K.
Solvay Pharmaceuticals B.V.
LandOfFree
Imidazoline derivatives having CB 1 -antagonistic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazoline derivatives having CB 1 -antagonistic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazoline derivatives having CB 1 -antagonistic activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3893738